Type/Product Area

Terms/Details (Date)


Undisclosed company

The unnamed partner licensed rights to use Intravail delivery technology with undisclosed pediatric therapeutics

The Intravail technology allows intranasal delivery of peptide and protein therapeutics; terms of the deal were not disclosed (8/1)


Intranasal Technology Inc.*

Expanded a deal to apply Aegis' Intravail delivery technology to intranasal heparin and beta-interferon

Terms of the deal were not disclosed (6/20)

Agilix Corp.*

Protana Inc.*

Protana got a nonexclusive license to Agilix's i-PROT proteomics technology

Protana will use the technology in its proteomic services, including biomarker discovery; terms were not disclosed (7/21)

Aldevron LLC*

CytoGenix Inc. (OTC BB:CYGX)

Aldevron will test the activity of a CytoGenix DNA vaccine against hepatitis B

Aldevron will use use its Genetic Immunization and Antibody technology in the effort; terms were not disclosed (8/2)


Cephalon Inc. (CEPH)

Agreement for the commercialization of Vivitrex; Alkermes would get $110M more upon FDA approval, filed an NDA for the alcohol-dependence drug in March

Alkermes gets $160M in cash up front; it and could get up to another $220M in sales-based milestones; they would share profits on a 50-50 basis (6/24)


MWG Biotech AG (Germany; FSE:NWUG)

MWG got nonexclusive rights to provide research products and services under Alnylam RNA interference patents

Terms of the license to the Kreutzer- Limmer patent family were not disclosed (7/25)


Nastech Pharmaceutical Co. Inc.(NSTK)

Nastech got an exclusive license to develop and sell RNAi therapeutics directed against TNF-alpha

Alnylam gets up-front and annual payments and is entitled to milestone payments and royalties on sales of covered products (7/20)


Eurogentec SA* (Belgium)

Eurogentec got nonexclusive rights to provide research products and services under Alnylam RNA interference patents

The Kreutzer-Limmer patent family covers short interfering RNAs and their use to mediate RNAi in mammalian cells; terms of the deal were not disclosed (7/12)

Aphton Corp.

VaxGen Inc. (VXGN)

VaxGen's South Korean joint venture Celltrion got rights to the cancer antibody IGN311 in certain Asian countries, including Japan

Igeneon AG, Aphton's subsidiary in Austria, potentially will get $6M in milestone payments and royalties on sales; Celltrion also will provide development and manufacturing services related to the product (7/25)


InterMune Inc. (ITMN)

Extended and expanded a 2002 deal to develop small-molecule inhibitors of the hepatitis C virus NS3/4 protease

InterMune is funding preclinical efforts at Array and would develop and sell resulting products; Array is entitled to milestone and royalty payments (7/19)


Targeted Molecular Diagnostics LLC*

Three-year deal to develop cancer biomarkers on the Auto-Genomics Infiniti platform

Terms of the deal were not disclosed (7/27)


MedImmune Inc. (MEDI)

Collaboration to discover and develop small-molecule drugs in the area of inflammatory disease

Avalon will identify lead compounds; Med- Immune has all other responsibilities; Avalon gets an up-front payment, R&D support and potential milestone and royalty payments (6/20)


BioLineRx Ltd.* (Israel)

BioLineRx licensed BL-2030, a soluble receptor that targets cancer cells

Terms of the exclusive, worldwide license were not disclosed (6/20)


Biosite Inc. (BSTE)

Deal to review cerebrovascular injury targets discovered with Banyan's animal model of cerebral injury

Biosite may select targets that Banyan nom-inates, and then would make antibodies to those targets, which would be used to create assays; terms of the deal were not disclosed (8/1)

owned by Arrow-
head Research
Corp.; ARWR)

Benitec Ltd. (Australia; ASX: BLT)

Benitec got exclusive rights to use polymeric nucleic acid delivery technology with its RNAi-based therapeutic for hepatitis C virus

Calando gets an up-front payment and potential milestone and royalty payments related to the HCV drug (6/21)

(Japan) and
Crystal Genomics
(South Korea)

Rigel Pharmaceuticals Inc. (RIGL)

Service agreement in the field of structure-based drug design

Carna and Crystal will provide services to Rigel under undisclosed terms (6/20)

Cellectis SA*

Ozgene Pty. Ltd.* (Australia)

Ozgene got a nonexclusive license to a patent covering replacement or insertion of a gene in a eukaryotic genome

Ozgene got rights related to the creation, development and sales of knock-in mice; terms of the deal were not disclosed (7/12)

Cellectis SA*

Xenogen Corp. (XGEN)

Xenogen got a nonexclusive license to a patent covering replacement or insertion of a gene in an eukaryotic genome

Xenogen will use the technology for creating knock-in mice; terms of the deal were not disclosed (6/29)

ChemDiv Inc.*

Euroscreen SA* (Belgium)

Partnership to discover and develop drugs against GPCR family chemokine targets

They intend to combine expertise in the effort, and share income from partnering clinical and preclinical candidates (7/1)

Chiron Corp.
(CHIR) and
Diagnostics Inc.

OraSure Technologies Inc. (OSUR)

OraSure got nonexclusive rights to certain patents covering hepatitis C virus

OraSure intends to use the technology in a diagnostic product; it will make up-front and royalty payments for the license (8/2)


Tranzyme Pharma Inc.*

CiVentiChem will provide medicinal chemistry and other services for Tranzyme

The goal is to advance development of Tranzyme's small-molecule products; terms of the deal were not disclosed (6/29)

Compugen Ltd.
(Israel; CGEN)

Biosite Inc. (BSTE)

Biosite got rights to develop immunoassay-based diagnostics using biomarkers discovered by Compugen

Compugen is entitled to milestone payments and royalties from resulting prod- ucts; Compugen retains therapeutic rights, and would pay Biosite milestones and royalties on those products (6/20)

Crucell NV
(the Netherlands;
Biologics (the

Chiron Corp. (CHIR)

Chiron got rights to test the PER.C6 cell line for use in manufacturing a prophylactic hepatitis C vaccine candidate

Terms of the deal were not disclosed (8/16)

Crucell NV
(the Netherlands;
Biologics (the

Symphogen A/S* (Denmark)

Symphogen got rights to use the PER.C6 cell line for producing its recombinant polyclonal antibodies

Symphogen will pay a signing fee and annual maintenance fees; further terms were not disclosed (7/15)


Debiopharm SA* (Switzerland)

Debiopharm got rights to develop PTR- 62, a peptide drug for the treatment of myasthenia gravis

Debiopharm intends to out-license the product later; DeveloGen is entitled to milestone and royalty payments (8/16)

DxS Ltd.*

Cepheid Inc. (CPHD)

Cepheid got rights to use Scorpions probe technology in a number of applications

Cepheid intends to apply the technology to industrial markets; its license excludes clinical diagnostics, wine production and detection of chemicals used in agriculture (7/20)

Science Ltd.*

Prolysis Ltd.* (UK)

They extended collaboration on advancing Prolysis' bacterial cell biology and antibiotic development programs

They now will focus on out- or in-licensing opportunities; terms of the deal were not disclosed (6/17)


Miraculins Inc. (Canada; TSE:MOM)

Miraculins purchased all rights to a number of patents and discoveries related to the diagnosis and treatment of cancers

Europroteome is in receivership; Miraculins has no further milestone or royalty obligations in the deal (6/22)

Evolva Biotech

AnalytiCon Discovery GmbH* (Germany)

Collaboration to generate and optimize nuclear receptor agonists and related compounds

Evolva will create and optimize the agonists; AnalytiCon will de-replicate, identify and scale-up the compounds; terms of the deal were not disclosed (6/30)

Galapagos NV

Celera Genomics Group (NYSE:CRA)

Galapagos will provide technology and adenoviral reagents for Celera research

Galapagos will construct recombinant adenoviruses harboring genes selected by Celera; it will receive undisclosed payments for the work (6/20)


Xpention Genetics Inc. (OTC BB:XPNG)

GeneThera will provide research services for development of a cancer detection test in animals and humans

Under one contract GeneThera will get $20,000 per month for one year to develop a test for animals; GeneThera will get $10,000 per month under a second contract to extend the technology into human testing (7/19)

Genmab A/S
(Denmark; CSE:

Serono SA (Switzerland; NYSE:CRA)

Serono got worldwide rights to HuMax-CD4, a fully human monoclonal antibody for treating T-cell lymphomas that's in Phase III trials

Genmab gets a $20M license payment, and a $50M equity investment from Serono at a premium; Genmab could get up to $145M more in regulatory and sales milestones, as well as royalties on resulting sales (8/18)

Hyalose LLC*

Meditech Research Ltd. (Australia; ASX:MTR)

Collaboration to evaluate hyaluronic acid molecules for their ability to act as targeting agents in drug delivery systems

The HA molecules are produced using recombinant technology developed at the University of Oklahoma and licensed to Hyalose; terms of the deal were not disclosed (7/7)



Iconix will provide chemo-genomic analyses on candidate compounds from Neurocrine

Iconix will apply its DrugMatrix technology to at least 12 Neurocrine compounds; terms of the deal were not disclosed (7/12)

Icoria Inc.

Isis Pharmaceuticals Inc. (ISIS)

Agreement to identify biomarkers of toxicity in animal models

Icoria will use its metabolomics platform to characterize differences in biochemical profiles between treated and untreated animal subjects and to identify those biochemicals that are specifically affected by treatment (8/23)


Genentech Inc. (NYSE:DNA)

Genentech got exclusive rights to use ImmunoGen's Tumor-Activated Prodrug technology with antibodies to an undisclosed target

ImmunoGen gets a $1M license payment and is entitled to milestone and royalty payments; Genentech now has taken three licenses to the TAP technology (7/26)

Jurilab Ltd.*

Nanogen Inc. (NGEN)

Nanogen acquired certain rights to develop diagnostic products based on genes and markers discovered by Jurilab; it also will distribute Jurilab's pharmaco- genomic products and services

Nanogen made a €1.25M investment for a stake of less than 20% in Jurilab, and will invest that much again in six months; Nanogen also got an option to purchase all of Jurilab; terms were not disclosed (7/26)

Large Scale
Biology Corp.

BioCatalytics Inc.*

Collaboration to apply their technologies to develop improved enzymes for chemical synthesis

LSBC gets a license fee for use of its protein- improvement technologies, and would get royalties on any resulting sales (8/17)

Genetics Inc.


Collaboration to jointly develop and market antibody drugs for certain targets discovered by Lexicon

Lexicon will submit targets and XOMA will generate antibodies to them; costs and profits will be allocated 65% to Lexicon and 35% to XOMA; XOMA will have manufactu- ring responsibility (6/21)

Medarex Inc.

Genmab A/S (Denmark; CSE:GEN)

Genmab licensed European and Asian rights to use UltiMAb technology in anti-bodies raised against the CD4 antigen, including HuMax-CD4

Medarex gets $2M up front and is entitled to milestone and license fee payments up to $12.5M; it also would get royalties that could reach double digits; Genmab now has worldwide rights to HuMax-CD4 (6/30)

Mimitopes Pty.
unit of PharmAust
Ltd.; ASX:PAA)

Phylogica Ltd. (Australia; ASX:PYC)

Partnership to pool technologies to develop next- generation peptide drugs

They will use Phylogica's Phylomer and Mimitopes' Synthase technologies in the effort; terms of the deal were not disclosed (8/15)

Neovacs SA*

Debiopharm SA* (Switzerland)

Collaboration to develop Neovacs' tumor necrosis factor alpha kinoid and related programs

Debiopharm will fund the program, and make up-front and milestone payments in cash and equity; Neovacs also would be entitled to royalties on sales (6/27)


Pharming Group NV (the Nertherlands; Euronext:PHARM)

Collaboration to combine NovaThera's biomaterial products with Pharming's recombinant proteins

NovaThera is entitled to milestone and royalty payments in the deal; Pharming gets rights to resulting products (7/12)

Thera Inc.*

Lexicon Genetics Inc. (LEXG)

Odyssey will characterize the pathway activity of certain Lexicon compounds in human cells

Terms of the deal were not disclosed (7/20)


Bavarian Nordic A/S (Denmark; CSE:BAVA)

Cross-licensing deal covering modified vaccinia ankara and PrimeBoost technologies

Oxxon got certain rights to MVA technology and Bavarian Nordic got rights to PrimeBoost; each would pay the other royalties on any resulting sales (7/1)

Group NV
(the Netherlands;

AgResearch Ltd.* (New Zealand)

Partnership under which AgResearch will produce recombinant human lactoferrin for Pharming

AgResearch got a research license to technology for producing recombinant proteins; Pharming will have the first right to review products from AgResearch's protein discovery and R&D projects (6/30)

Protein Design
Labs Inc.

Biogen Idec Inc. (BIIB)

Deal to jointly develop and market three Phase II PDL antibodies: daclizumab, M200 (volociximab) and HuZAF (fontolizumab)

PDL gets $40M up front and a $100M equity investment; it also could earn up to $560M in development milestones and $100M in commercialization milestones; they will share costs and profits in the U.S. and Europe, and PDL would get royalties elsewhere (8/2)

Protein Design
Labs Inc.

Genentech Inc. (NYSE:DNA)

Genentech sublicensed rights to antibody-drug conjugate technology against the PR1 antigen,which has applications in prostate cancer

PDL, which got certain sublicensing rights from Seattle Genetics Inc., is entitled to an up-front licensing fee along with potential milestone and royalty payments (6/22)


Immune Control Inc.*

Collaboration to develop lead compounds for diseases with immunological causes

Provid will use its technologies to develop the lead compounds; terms of the deal were not disclosed (6/17)


Cellumen Inc.*

Cellumen got nonexclusive rights to use RheoGene's RheoSwitch and RheoPlex technologies

Cellumen intends to develop systems cell biology screening products and offer them to drug developers; they also will develop and validate mammalian cell lines; terms were not disclosed (7/26)


Biovitrum AB* (Sweden)

Biovitrum got worldwide rights to Santhera's DPP-IV inhibitor program for treating Type II diabetes and other metabolic diseases

Santhera gets €4M up front, and gets a certain percentage of future revenues, which could include milestones and royalties from sublicenses (8/17)

Scancell Ltd.*

GTC Biotherapeutics Inc. (GTCB)

Collaboration centered on Scancell's SC101 anticancer monoclonal antibody, which targets Lewis y/b

They will evaluate expression of the MAb using GTC's transgenic production platform, an effort that could lead to a collaboration on clinical development; terms were not disclosed (7/28)

Genetics Inc.

Progenics Pharmaceuticals Inc. (PGNX) and Cytogen Corp. (CYTO)

PSMA Development Co. got rights to use antibody- drug conjugate technology for targeting prostate-specific membrane antigen

PSMA Development Co. is a joint venture between Progenics and Cytogen; Seattle Genetics gets a $2M access fee, annual maintenance fees and research support payments, as well as potential milestones and royalties (6/20)


CXR Biosciences Ltd.* (UK)

Collaboration to establish a battery of in vitro screens for improving selection of candidate drug molecules

Serologicals subsidiary Upstate Group will work with CXR in the effort; terms of the deal were not disclosed (6/22)


ImaRx Therapeutics Inc.*

ImaRx got a license to fluorocarbon-based oxygen- delivery technology

ImaRx's sublicense on four patents is exclusive; Sonus would get royalties on any resulting sales (7/11)

SR Pharma

Introgen Therapeutics Inc. (INGN)

Introgen is supporting work at SR Pharma through a $3M investment

Introgen gained an 8.3% stake in SR Pharma and expanded its presence into Europe; further terms were not disclosed (7/28)


ReNeuron Holdings plc* (UK)

ReNeuron licensed rights to use c-mycER conditionally immortalized adult human neural stem cell technology

StemCells got an equity interest in ReNeuron and a cross- icense to exclusively use ReNeuron's technology for certain diseases and conditions; each would pay the other milestones and royalties on resulting products (7/6)


Cambridge Antibody Technology Group plc (UK; CATG)

Patent license agreement giving Symphogen access to CAT's antibody phage display patents for research purposes and to develop and commercialize antibody products

Symphogen made an up-front payment and exercised its first option to develop and commercialize Sym001 for idiopathic thrombocytopenic purpura and hemolytic disease of newborns; as a result, Symphogen paid a product license fee, and may make future milestone and royalty payments to CAT (8/23)


MacroGenics Inc.*

MacroGenics acquired an anti-CD3 monoclonal antibody for treating Type I diabetes and other autoimmune diseases

The product has been in a Phase I trial; terms of the deal were not disclosed (7/18)

Valentis Inc.

Biolitec AG (Germany; FSE:BIB)

Biolitec got worldwide rights to use pegylated liposomal technology from Valentis to develop new drug formulations

Valentis gets an up-front payment and is eligible to receive milestone payments and royalties on any resulting sales (6/22)


* Private companies are indicated with an asterisk.

Unless otherwise notes, the trading symbols listed for public biotechnology companies are on the Nasdaq market.

AIM = Alternative Investment Market; ASX = Australian Stock Exchange; CSE = Copenhagen Stock Exchange; FSE = Frankfurt Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange

No Comments